Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
Our results do not support the antitumor activity of single-agent copanlisib in tumors with PTEN loss regardless of mutation or deletion status or <i>PTEN</i> deleterious mutations with PTEN expression.
Authors
- Alice P. Chen (ORCID: https://orcid.org/0000-0002-2919-4326)
- Lyndsay N. Harris (ORCID: https://orcid.org/0000-0002-9774-6719)
- Raymond Liu (ORCID: https://orcid.org/0000-0002-4667-9632)
- Keith T. Flaherty (ORCID: https://orcid.org/0000-0002-3402-0478)
- Peter James O'Dwyer (ORCID: https://orcid.org/0000-0002-9302-4073)
- Jordi Rodón (ORCID: https://orcid.org/0000-0001-6467-3632)
- Larry Rubinstein (ORCID: https://orcid.org/0000-0002-9720-9737)
- David R. Patton (ORCID: https://orcid.org/0000-0003-3855-0166)
- Lisa M. McShane (ORCID: https://orcid.org/0000-0001-8195-3206)
- Daniela A. Bota (ORCID: https://orcid.org/0000-0002-9680-9060)
- Gary L. Buchschacher (ORCID: https://orcid.org/0009-0000-5713-4155)
- Carlos L. Arteaga (ORCID: https://orcid.org/0000-0003-0870-9586)
- Michael A. Davies (ORCID: https://orcid.org/0000-0002-0977-0912)
- Paul Swiecicki (ORCID: https://orcid.org/0000-0003-2286-3555)
- Barbara A. Conley (ORCID: https://orcid.org/0000-0002-1445-1684)
- Mohamed A. Gouda (ORCID: https://orcid.org/0000-0003-4829-6739)
- Filip Jankú (ORCID: https://orcid.org/0000-0002-8123-4065)
- James V. Tricoli (ORCID: https://orcid.org/0000-0003-3975-8516)
- Robert J. Gray (ORCID: https://orcid.org/0000-0002-5724-4917)
- Stanley R. Hamilton (ORCID: https://orcid.org/0000-0002-8331-1052)
- Zihan Wei (ORCID: https://orcid.org/0000-0001-9234-3497)
- P. Mickey Williams (ORCID: https://orcid.org/0000-0002-3309-5988)
- Victoria Wang
Institutions
- City Of Hope National Medical Center (US)
- Kaiser Permanente (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Michigan (US)
- Massachusetts General Hospital (US)
- Southwestern Medical Center (US)
- ECOG-ACRIN Cancer Research Group (US)
- Dana-Farber Cancer Institute (US)
- Frederick National Laboratory for Cancer Research (US)
- Colorado Permanente Medical Group (US)
- National Cancer Institute (US)
- Harold C. Simmons Comprehensive Cancer Center
- University of Pennsylvania (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1200/po-24-00451
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00